Marshall Wace North America’s Amphastar Pharmaceuticals AMPH Stock Holding History

Marshall Wace North America’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,165	Closed	-$47K	–	1138
2020 Q1	$47K	Buy	+3,165	New	+$55.1K	﹤0.01%	1078
2019 Q4	–	Sell	-11,191	Closed	-$222K	–	1269
2019 Q3	$222K	Buy	+11,191	New	+$233K	﹤0.01%	946
2018 Q2	–	Sell	-163,494	Closed	-$3.07M	–	1365
2018 Q1	$3.07M	Buy	163,494 +9,380	+6%	+$176K	0.02%	691
2017 Q4	$2.96M	Buy	+154,114	New	+$2.88M	0.02%	726
2017 Q2	–	Sell	-14,325	Closed	-$215K	–	1279
2017 Q1	$215K	Buy	+14,325	New	+$225K	﹤0.01%	909

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Marshall Wace North America's AMPH Position: Q2 2020 in Review

Marshall Wace North America sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2020, closing a stake of 3,165 shares — an estimated $47K sold.

Marshall Wace North America first reported a position in AMPH in Q1 2017 and held it in 5 quarters. The position peaked at $3.07M in Q1 2018. 135 funds tracked by Wall St. Rank hold AMPH as of Q2 2020.

Marshall Wace North America reported no remaining Amphastar Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Marshall Wace North America sold 3,165 Amphastar Pharmaceuticals shares in Q2 2020, an estimated $47K.
Marshall Wace North America first reported a position in Amphastar Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Marshall Wace North America's Amphastar Pharmaceuticals position peaked at $3.07M in Q1 2018.
135 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.